Focusing on innovative off-the-shelf immunotherapeutics, we turn to multispecific antibody xLinkTsAb platform to offer additional specificity for tumors or enhanced immune-cell activation. Our own property multispecific constructs permit to stimulate direct tumor killing by engaging cytotoxic T cells in a tumor antigen-dependent way.
xLinkTsAb T cell engager
TA targeting with high selectivity
Re-direct T cells to cancer cells
Activate T cells only when TA is engaged
Cross-linking dependent activity
Dual signaling of CD3 and CD137
Superior preclinical efficacy
IgG like design; patent filed
Broad TA positive tumors in the clinic
CD19, CD20, BCMA, DLL3, PSMA, B7H3, other TA projects ongoing
Lyvgen Biopharma engaged in development of innovative cancer treatment, is open to collaborate or out-license our pipelines or platform technology. Please contact us to explore collaboration opportunities.
Lyvgen is a biotech company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs.